DNAzymes as potential therapeutic molecules

Current Opinion in Molecular Therapeutics

Volumn 9, Issue 2, 2007, Pages 132-136

  Isaka, Yoshitaka ^a  

^a OSAKA UNIVERSITY   (Japan)

Author keywords

Biosensing; DNAzyme; Egr 1; Locked nucleic acid; Phosphorothioate; Ribozyme

Indexed keywords

BIOLOGICAL MARKER; DEOXYRIBOZYME; PROTEIN C JUN;

ARTERY INJURY; BREAST CARCINOMA; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG STABILITY; HEART MUSCLE INJURY; IN VIVO STUDY; INFLAMMATION; NONHUMAN; REVIEW; VIRUS INFECTION;

ANIMALS; BIOLOGICAL MARKERS; DNA, CATALYTIC; DRUG DELIVERY SYSTEMS; ENZYME STABILITY; HUMANS;

EID: 34247277243     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Santoro SW, Joyce GF: A general purpose RNA-cleaving DNA enzyme. Proc Natl Acad Sci USA (1997) 94(9):4262-4266. •• This is the landmark paper describing the catalytic DNAzymes 10-23 and 8-17.
2. Sen D, Geyer CR: DNA enzymes. Curr Opin Chem Biol (1998) 2(6):680-687.
3. Cairns MJ, King A, Sun LQ: Nucleic acid mutation analysis using catalytic DNA. Nucleic Acids Res (2000) 28(3):E9.
4. Cairns MJ, King A, Sun LQ: Optimization of the 10-23 DNAzymesubstrate pairing interactions enhanced RNA cleavage activity at purine-cytosine target sites. Nucleic Acids Res (2003) 31(11):2883-2889.
5. Santiago FS, Lowe HC, Kavurma MM, Chesterman CN, Baker A, Atkins DG, Khachigian LM: New DNA enzyme targeting Egr-1 mRNA inhibits vascular smooth muscle proliferation and regrowth after injury. Nat Med (1999) 5(11):1264-1269. •• This paper showed the first therapeutic application of 10-23 DNAzyme in vivo.
6. Lowe HC, Chesterman CN, Khachigian LM: Catalytic antisense DNA molecules targeting Egr-1 inhibit neointima formation following permanent ligation of rat common carotid arteries. Thromb Haemost (2002) 87(1):134-140.
7. Lowe HC, Fahmy RG, Kavurma MM, Baker A, Chesterman CN, Khachigian LM: Catalytic oligodeoxynucleotides define a key regulatory role for early growth response factor-1 in the porcine model of coronary in-stent restenosis. Circ Res (2001) 89(8):670-677.
8. Fahmy RG, Dass CR, Sun LQ, Chesterman CN, Khachigian LM: Transcription factor Egr-1 supports FGF-dependent angiogenesis during neovascularization and tumor growth. Nat Med (2003) 9(8):1026-1032.
9. Mitchell A, Dass CR, Sun LQ, Khachigian LM: Inhibition of human breast carcinoma proliferation, migration, chemoinvasion and solid tumour growth by DNAzymes targeting the zinc finger transcription factor EGR-1. Nucleic Acids Res (2004) 32(10):3065-3069.
10. Nakamura H, Isaka Y, Tsujie M, Rupprecht HD, Akagi Y, Ueda N, Imai E, Hori M: Introduction of DNA enzyme for Egr-1 into tubulointerstitial fibroblasts by electroporation reduced interstitial α-smooth muscle actin expression and fibrosis in unilateral ureteral obstruction (UUO) rats. Gene Ther (2002) 9(8):495-502.
11. Isaka Y, Nakamura H, Mizui M, Takabatake Y, Horio M, Kawachi H, Shimizu F, Imai E, Hori M: DNAzyme for TGF-β suppressed extracellular matrix accumulation in experimental glomerulonephritis. Kidney Int (2004) 66(2):586-590.
12. Zhang G, Dass CR, Sumithran E, Di Girolamo N, Sun LQ, Khachigian LM: Effect of deoxyribozymes targeting c-Jun on solid tumor growth and angiogenesis in rodents. J Natl Cancer Inst (2004) 96(9):683-696.
13. Fahmy RG, Waldman A, Zhang G, Mitchell A, Tedla N, Cai H, Geczy CR, Chesterman CN, Perry M, Khachigian LM: Suppression of vascular permeability and inflammation by targeting of the transcription factor c-Jun. Nat Biotechnol (2006) 24(7):856-863. • This paper demonstrated that DNAzyme targeting c-jun may be a useful therapeutic tool in anti-inflammatory diseases using several murine model.
14. Zhang G, Luo X, Sumithran E, Pua VS, Barnerson RS, Halliday GM, Khachigian LM: Squamous cell carcinoma growth in mice and in culture is regulated by c-Jun and its control of matrix metalloproteinase-2 and -9 expression. Oncogene (2006) 25(55):7260-7266.
15. Zhang L, Gasper WJ, Stass SA, Ioffe OB, Davis MA, Mixson AJ: Angiogenic inhibition mediated by a DNAzyme that targets vascular endothelial growth factor receptor 2. Cancer Res (2002) 62(19):5463-5469.
16. Bhindi R, Khachigian LM, Lowe HC: DNAzymes targeting the transcription factor Egr-1 reduce myocardial infarct size following ischemia-reperfusion in rats. J Thromb Haemost (2006) 4(7):1479-1483.
17. Iversen PO, Nicolaysen G, Sioud M: DNA enzyme targeting TNF-α mRNA improves hemodynamic performance in rats with postinfarction heart failure. Am J Physiol Heart Circ Physiol (2001) 281(5):H2211- H2217.
18. Xiang G, Seki T, Schuster MD, Wittowski P, Boyle AJ, See F, Martens TP, Kocher A, Sondermeijer H, Krum H, Itescu S: Catalytic degradation of vitamin D up-regulated protein 1 mRNA enhances cardiomyocyte survival and prevents left ventricular remodeling after myocardial ischemia. J Biol Chem (2005) 280(47):39394-39402.
19. Xiang G, Schuster MD, Seki T, Kocher AA, Eshghi S, Boyle A, Itescu S: Down-regulation of plasminogen activator inhibitor 1 expression promotes myocardial neovascularization by bone marrow progenitors. J Exp Med (2004) 200(12):1657-1666.
20. Chakraborti S, Banerjea AC: Inhibition of HIV-1 gene expression by novel DNA enzymes targeted to cleave HIV-1 TAR RNA: Potential effectiveness against all HIV-1 isolates. Mol Ther (2003) 7(6):817-826.
21. Hou W, Wo JE, Li MW, Liu KZ: In vitro cleavage of hepatitis B virus C mRNA by 10-23 DNA enzyme. Hepatobiliary Pancreat Dis Int (2005) 4(4):573-576.
22. Trepanier J, Tanner JE, Momparler RL, Le ON, Alvarez F, Alfieri C: Cleavage of intracellular hepatitis C RNA in the virus core protein coding region by deoxyribozymes. J Viral Hepat (2006) 13(2):131-138.
23. Boden D, Pusch O, Lee F, Tucker L, Ramratnam B: Human immunodeficiency virus type 1 escape from RNA interference. J Virol (2003) 77(21):11531-11535.
24. Dass CR, Saravolac EG, Li Y, Sun LQ: Cellular uptake, distribution, and stability of 10-23 deoxyribozymes. Antisense Nucleic Acid Drug Dev (2002) 12(5):289-299.
25. Kurreck J: Antisense technologies. Improvement through novel chemical modifications. Eur J Biochem (2003) 270(8):1628-1644.
26. Sun LQ, Cairns MJ, Gerlach WL, Witherington C, Wang L, King A: Suppression of smooth muscle cell proliferation by a c-myc RNA-cleaving deoxyribozyme. J Biol Chem (1999) 274(24):17236-17241.
27. Schubert S, Gul DC, Grunert HP, Zeichhardt H, Erdmann VA, Kurreck J: RNA cleaving '10-23' DNAzymes with enhanced stability and activity. Nucleic Acids Res (2003) 31(20):5982-5992.
28. Levin AA: A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. Biochim Biophys Acta (1999) 1489(1):69-84.
29. 3 mRNA down-regulate expression of the targeted integrins and inhibit endothelial cell capillary tube formation in fibrin and matrigel. J Biol Chem (2002) 277(9):6779-6787.
30. Petersen M, Bondensgaard K, Wengel J, Jacobsen JP: Locked nucleic acid (LNA) recognition of RNA: NMR solution structures of LNA:RNA hybrids. J Am Chem Soc (2002) 124(21):5974-5982.
31. Vester B, Wengel J: LNA (locked nucleic acid): High-affinity targeting of complementary RNA and DNA. Biochemistry (2004) 43(42):13233-13241.
32. Vester B, Hansen LH, Lundberg LB, Babu BR, Sorensen MD, Wengel J, Douthwaite S: Locked nucleoside analogues expand the potential of DNAzymes to cleave structured RNA targets. BMC Mol Biol (2006) 7:19. • LNAzyme can enhance the folding of the enzyme's catalytic loop as well as alter the hybridization capacity.
33. Dass CR: Deoxyribozymes: Cleaving a path to clinical trials. Trends Pharmacol Sci (2004) 25(8):395-397.
34. Fahmy RG, Khachigian LM: Locked nucleic acid modified DNA enzymes targeting early growth response-1 inhibit human vascular smooth muscle cell growth. Nucleic Acids Res (2004) 32(7):2281-2285.
35. Takabatake Y, Isaka Y, Mizui M, Kawachi H, Shimizu F, Ito T, Hori M, Imai E: Exploring RNA interference as a therapeutic strategy for renal disease. Gene Ther (2005) 12(12):965-973.
36. Sando S, Sasaki T, Kanatani K, Aoyama Y: Amplified nucleic acid sensing using programmed self-cleaving DNAzyme. J Am Chem Soc (2003) 125(51):15720-15721.
37. Stojanovic MN, Stefanovic D: A deoxyribozyme-based molecular automaton. Nat Biotechnol (2003) 21(9):1069-1074. • The DNAzyme-based automaton executed a program encoded through a spatial distribution of nucleic acid catalysts behaving as logic gates.
38. 2+ with a DNAzyme-based biosensor.
39. Stojanovic MN, Mitchell TE, Stefanovic D: Deoxyribozyme-based logic gates. J Am Chem Soc (2002) 124(14):3555-3561.
40. Liu J, Lu Y: Improving fluorescent DNAzyme biosensors by combining inter- and intramolecular quenchers. Anal Chem (2003) 75(23):6666-6672.
41. Wang DY, Lai BH, Sen D: A general strategy for effector-mediated control of RNA-cleaving ribozymes and DNA enzymes. J Mol Biol (2002) 318(1):33-43.
42. Cho EJ, Yang L, Levy M, Ellington AD: Using a deoxyribozyme ligase and rolling circle amplification to detect a non-nucleic acid analyte, ATP. J Am Chem Soc (2005) 127(7):2022-2023.